OnCo
peoplePerson

Josep Tabernero

Colorectal cancer trialist who led BEACON and BREAKWATER, bringing targeted therapy to BRAF-mutant disease; former ESMO President.

Josep Tabernero directs VHIO and led BEACON CRC (encorafenib plus cetuximab) and BREAKWATER, which established first-line targeted therapy for BRAF V600E colorectal cancer. He was ESMO President in 2018-2019.

Role
Director, Vall d'Hebron Institute of Oncology (VHIO); Head of Medical Oncology, Vall d'Hebron University Hospital
Specialisms
Colorectal cancerGastrointestinal oncologyEarly drug developmentPrecision medicine
Profiles

Papers

2top
TitleJournalYear
Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON)NEJM2019
Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer (BREAKWATER)NEJM2025

Key papers

1top
rctNew England Journal of Medicine 2025changed practice
BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer

Patients with newly diagnosed metastatic colorectal cancer whose tumour carries a BRAF V600E mutation, which is about 8-12% of cases, should now be offered encorafenib and cetuximab together with FOLFOX from the start rather than after chemotherapy fails; median survival has roughly doubled to about two and a half years. BRAF testing at diagnosis is therefore essential, alongside RAS and mismatch repair testing. The regimen is more toxic than chemotherapy alone.

Connected

9top

Pages like this

not linked directly; found by shared links

cancers

1
Colorectal cancer

targets

2
BRAFEGFR

drugs

2
ApprovedMonoclonal antibody (anti-EGFR)
Cetuximab · Erbitux
ApprovedSmall-molecule kinase inhibitor (BRAF)
Encorafenib · Braftovi

institutions

2
European Society for Medical Oncology (ESMO)Vall d'Hebron University Hospital / VHIO

trials

1
BREAKWATER

key papers

1
BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer